Table 3 First line chemotherapy and response
From: Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population
Treatment modality | N (%) | Â | |
|---|---|---|---|
| Â | Response to chemotherapy - n (%) | ||
| Â | PR | CR | |
Cytarabine-based | 27 (40.9) | 5 (18.5) | 22 (81.5) |
 R-CHOP/R-ARAC | 6 (9.1) | 2 (33.3) | 4 (66.7) |
 R-CHOP/R-DHAP | 1 (1.5) | – | 1 (100) |
 R-HyperCVAD | 16 (59.3) | 1 (6.25) | 15 (93.8) |
 HyperCVAD | 2 (3.0) | 1 (50) | 1 (50) |
 R-BAC | 2 (3.0) | 1 (50) | 1 (50) |
Others | 29 (51.8) | 8 (27.5) | 19 (65.5) |
 R-Bendamustine | 7 (10.6) | 2 (28.6) | 5 (71.4) |
 VRCAP | 3 (4.5) | – | 3 (100) |
 R-CHOPa | 16 (24.2) | 4 (25) | 10 (62.5) |
 R-CVP | 1 (1.5) | 1 (100) | – |
 CHOP | 2 (3.0) | 1 (50) | 1 (50) |
Maintenance rituximab | |||
 Yes | 25 (44.6) |  |  |
 No | 31 (55.4) |  | |
Autologous stem cell transplant | |||
 Yes | 5 (7.6) |  | |
 No | 61 (92.4) | ||
Non-chemotherapy | |||
 Watch and wait only | 1 (1.8) |  | |
 Radiation only | 3 (4.6) |  | |
 Best Supportive Care | 3 (4.6) |  | |
 Unknown | 3 (4.6) |  | |